BioMerieux

BioMerieux’s Q1 2024 earnings show modest revenue growth and margin expansion driven by clinical diagnostics and infection‑control, yet regulatory changes, CAPEX risks, and fierce competition could weigh on future returns.

Valneva’s TBE vaccine stays in demand despite a shrinking global market thanks to 92.3% efficacy, a low adverse‑event profile, and fast regulatory approval in Europe and the U.S.

On Wednesday 5th of February Biomerieux trades -0.85 percent lower